Navigation Links
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The data are from an ongoing Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of its lead anti-cancer drug candidate, IT-101, in patients with inoperable or metastatic tumors. IT-101 is a conjugate of the potent anti-cancer drug camptothecin and Insert's proprietary drug delivery technology, Cyclosert(TM).

"The interim IT-101 study results look very promising," stated R. Bruce Stewart, Chairman of Arrowhead. "We were encouraged to see patients who have failed other chemotherapies complete the whole six cycles of treatment without disease progression."

The abstract's authors state that the stable disease rate, although not yet conclusive, is consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Patients that have completed the six cycle treatment regimen and showed stable disease or better are expected to continue to receive treatment on a compassionate care basis. The first person to enter the trial, a pancreatic cancer patient, is stable after 10 months.

"The type of dose limiting toxicity identified is consistent with the expectation for a camptothecin derivative," said Dr. Thomas Schluep, Chief Scientific Officer at Insert. "We are encouraged that, at dose levels that have promising efficacy, we have not seen some of the other deleterious side effects commonly experienced by patients receiving camptothecin class drugs."

Pharmacokinetics data were favorable and consistent with results from preclinical animal studies. In the patients studied, IT-101 showed longer half life, lower clearance and lower volume of distribution than seen in pati
'"/>




Page: 1 2 3

Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS International, ... Manufacturing Intelligence , today announces Infusion Chicago, ... event will be held Oct. 9-10, 2014, at ... designed to showcase the necessity for implementing a ... and Manufacturing Intelligence to gain insight into production ...
(Date:8/21/2014)... 2014  AliveCor, Inc. announced today that ... has granted the company clearance for its ... most common form of cardiac arrhythmia. AliveCor,s ... patients are experiencing AFib through real-time electrocardiogram ... based AliveCor® Heart Monitor, so physicians can ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014  The board ... ), a leading provider of clinical trial imaging solutions, ... been named chief financial officer, effective immediately.  Mr. Groff ... since August 2013.  He joined VirtualScopics in January 2006 ... in February 2013. "When the board of ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... Inc.,(Amex: CUR ) today announced that it ... Clinic pertaining to Targeted Spinal Cord,Therapeutics Delivery. All ... formerly of Cleveland Clinic, now at Emory University., ... are very pleased to have licensed-in these important ...
... today,announced the Company,s lead product, amadacycline, formerly PTK 0796, ... Breaker,poster presentation at the 48th Interscience Conference on Antimicrobial,Agents ... D.C.,from October 25 - October 28, 2008., More ... Sunday, October 26, 12:15 - 1:15 pm EST ...
Cached Medicine Technology:Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 2Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology 3Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2
(Date:8/22/2014)... For the first time an oncogenic somatic mutation ... transfection) protein has been identified in small cell lung ... within SCLC cell lines produced increased intracellular signaling and ... of lung cancer representing 15% of all lung cancers ... 85% of lung cancer, has been extensively examined for ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... 2014 CarePoint Health is proud ... Medicine, Geriatrics, Hospice and Palliative Care, Dr. Michelle ... Group. Their system welcomes Dr. Reisner to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
(Date:8/22/2014)... FRIDAY, Aug. 22, 2014 (HealthDay News) -- Back-to-school time ... plan that fits into the family schedules, an expert ... a child,s school year can also be the start ... Karin Richards, a professor of kinesiology at the University ... news release. With kids, extracurricular activities likely to ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... new study shows anemia may double the risk of ... erode the ability to live independently. Researchers say seniors ... are just above the traditional cut-off point for the ... declines than those who have normal blood hemoglobin levels.// ...
... than 2 million people worldwide and is caused by abnormal ... in seizures. More than half of those with epilepsy can ... is under way to determine just how effective surgery is ... epilepsy, //the most common form of the disorder.,Typically, about 80 ...
... today, be careful how much fluid you drink. Too much ... fatal outcome. ,The warning follows reports of several deaths from ... excessive drinking known as hyponatremic encephalopathy. Since the cause of ... Science Institute of South Africa, says it is preventable.,// ...
... low in saturated fats can lower bad cholesterol as effectively ... medication-free cholesterol control may be viable for some people. Researchers ... in okra, eggplant, soy proteins, oatmeal //and almonds resulted in ... just one month. ,Participants on a low-fat diet ...
... through activities such as reading, doing puzzles or playing ... cognitive abilities as you age. ,That's the message from ... of the New England Journal of Medicine. ,Researchers from ... found seniors who participated in mind-stimulating leisure activities had ...
... - When HIV-infected patients alternated their drug regimen ... longer than when one regimen was administered continuously. ... Therapy Combination against HIV-1) study. Dr. Javier Martinez-Picado, ... Spain, and others examined this alternating strategy among ...
Cached Medicine News:
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... Air Entrainment Nebulizers deliver particulate humidity in ... your chronic secretion patients. For your convenience, ... existing supply of sterile water., ,The ... FiO2's of 20-50% with a total flow ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Airial Handheld Ultrasonic Nebulizer has ... This compact, portable, and lightweight ... fast & quite treatments operating ... or DC auto adapter. , ...
Medicine Products: